Agilent launches NovoCyte Opteon flow cytometer



SANTA CLARA, Calif. – Agilent Technologies, Inc. (NYSE: ) has expanded its NovoCyte product line with the launch of the NovoCyte Opteon Spectral Flow Cytometer, a device that enhances the capabilities of flow cytometry, a key technology for cell analysis. The announcement coincides with the 10th anniversary of the NovoCyte platform, marking a decade of flow cytometry innovation.

NovoCyte Opteon is designed to support complex large-panel flow cytometry assays, allowing researchers to analyze more than 40 cell markers simultaneously. This advancement provides greater flexibility in experimental design and can have a significant impact on various fields of science, including basic research, drug discovery, and therapeutic development.

Equipped with up to 5 lasers and 73 high-quality detectors, NovoCyte Opteon is designed to meet the growing demand for high-dimensional, multi-parameter flow cytometry testing. Wang Xiaobo, vice president and general manager of Agilent's Cell Function and Phenotype business unit, said its user-friendly software package is designed to simplify workflows and make the system easy to use, maintain and automate.

Agilent's latest products are designed to provide researchers with a system that combines advanced spectroscopic capabilities with an intuitive design that allows customization to meet specific research requirements. The company emphasizes that NovoCyte Opteon's proprietary technology ensures optimized optical and electronic signal collection, real-time monitoring and consistent, reliable data collection.

The official launch of NovoCyte Opteon will take place at the CYTO 2024 conference in Edinburgh, Scotland, May 4-8, 2024. Approximately 18,000 employees worldwide.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

This announcement is based on an Agilent Technologies press release.

Investment Professional Insights

As Agilent Technologies (NYSE: A) launches its latest innovation in flow cytometry, the NovoCyte Opteon, it's worth noting the company's financial stability and market performance, especially given its recent product line expansion. According to InvestingPro data, Agilent has a strong market capitalization of US$40.16 billion, highlighting its important position in the field of analytical and clinical laboratory technology.

The company's dedication to innovation and growth is also reflected in its financial metrics. In the past 12 months as of the first quarter of 2024, Agilent's gross profit margin has remained stable at 50.56%, which shows that Agilent has strong cost control capabilities and efficient revenue generation capabilities. Additionally, its operating margin was 20.4%, showing the company's proficiency in profit management.

For investors focused on performance and stability, Agilent has a track record of maintaining dividend payments for 13 consecutive years, as highlighted in one of InvestingPro Tips. This consistency reflects the company's commitment to delivering shareholder value. Additionally, Agilent's share price has surged 33.67% over the past six months, indicating a positive market reaction and potential investors' confidence in its strategic direction.

For those interested in more in-depth analysis and other InvestingPro tips, Agilent's profile on InvestingPro provides a comprehensive overview of the company's financials and market potential.Readers can use coupon codes to find more insights and take advantage of special offers PRONEWS24 Enjoy an additional 10% discount on yearly or annual Pro and Pro+ subscriptions. Through another 12 InvestingPro Tips, investors can deepen their understanding of Agilent's market position and future prospects.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

This article was generated with the support of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *